Clinical Trials Logo

Filter by:
NCT ID: NCT00119977 Completed - Osteoarthritis Clinical Trials

Periacetabular Osteotomy.A Prospective Study With Reference to Cartilage, Migration and Bone Density

Start date: October 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of performing a periacetabular osteotomy on patients with hip dysplasia.

NCT ID: NCT00119769 Completed - HIV Infections Clinical Trials

The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients

Start date: February 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.

NCT ID: NCT00119457 Completed - Clinical trials for Venous Thromboembolism

Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.

NCT ID: NCT00119444 Completed - Osteoarthritis Clinical Trials

Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography

Start date: January 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the blood flow in acetabulum after periacetabular osteotomy by Positron Emission Tomography (PET).

NCT ID: NCT00118976 Completed - Clinical trials for Diabetic Nephropathy

Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease

Start date: March 2005
Phase: N/A
Study type: Interventional

The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy. The secondary aim is to evaluate the effect on blood pressure (24 hour ambulatory blood pressure) and kidney function (glomerular filtration rate (GFR)). The tertiary aim is to evaluate differences in response to treatment according to ACE/insertion/deletion (ID)-genotypes and other genetic variants in the genes of the renin angiotensin system.

NCT ID: NCT00118963 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes

Start date: January 2003
Phase: Phase 4
Study type: Interventional

Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of OHA to be combined with insulin. The aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. Methodology: Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart 30/70, BIAsp30) for a period of 12 months.

NCT ID: NCT00118950 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet

Start date: March 2001
Phase: Phase 4
Study type: Interventional

Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.

NCT ID: NCT00117520 Completed - Clinical trials for Healthy Elderly Citizens

The Effect of Caffeine in Elderly Citizens

Start date: July 2002
Phase: Phase 4
Study type: Interventional

The study investigated the effect of caffeine on physical performance in healthy citizens aged over 70 years. The main hypothesis was that 6 mg/kg caffeine would improve cycling endurance at 65% of expected maximal heart rate.

NCT ID: NCT00116948 Completed - Osteoarthrosis Clinical Trials

A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare two total hip replacement systems: Hip Resurfacing System (ReCap) versus Mallory-Head/Exeter.

NCT ID: NCT00116051 Completed - Osteoarthritis Clinical Trials

A Comparison of Two Surface Materials (Tantalum Versus Titanium Fiber Mesh) of Acetabular Components in Hip Arthroplasty

Start date: September 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two surface materials (tantalum versus titanium fiber mesh) of acetabular components in hip arthroplasty.